The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index; 7 of the 21 sources its claims cite were checked for support.
Mdm2 Binds to Nbs1 at Sites of DNA Damage and Regulates Double Strand Break Repair
Open accessAbstract
Mdm2 directly regulates the p53 tumor suppressor. However, Mdm2 also has p53-independent activities, and the pathways that mediate these functions are unresolved. Here we report the identification of a specific association of Mdm2 with Mre11, Nbs1, and Rad50, a DNA double strand break repair complex. Mdm2 bound to the Mre11-Nbs1-Rad50 complex in primary cells and in cells containing inactivated p53 or p14/p19ARF, a regulator of Mdm2. Further analysis revealed that Mdm2 directly bound to Nbs1 but not to Mre11 or Rad50. Amino acids 198-314 of Mdm2 were required for Mdm2/Nbs1 association, and neither the N terminus forkhead-associated and breast cancer C-terminal domains nor the C terminus Mre11 binding domain of Nbs1 mediated the interaction of Nbs1 with Mdm2. Mdm2 co-localized with Nbs1 to sites of DNA damage following gamma-irradiation. Notably, Mdm2 overexpression inhibited DNA double strand break repair, and this was independent of p53 and ARF, the alternative reading frame of the Ink4alocus. The delay in DNA repair imposed by Mdm2 required the Nbs1 binding domain of Mdm2, but the ubiquitin ligase domain in Mdm2 was dispensable. Therefore, Nbs1 is a novel p53-independent Mdm2 binding protein and links Mdm2 to the Mre11-Nbs1-Rad50-regulated DNA repair response.
Overview
CoChat Summary
TL;DR
Mdm2 directly binds Nbs1, a component of the Mre11-Nbs1-Rad50 DNA double-strand break repair complex, independently of p53 and ARF. Mdm2 overexpression delays DNA double-strand break repair in a manner requiring the Nbs1-binding domain of Mdm2 but not its ubiquitin ligase domain.
Key findings
- Mdm2 co-immunoprecipitated with Mre11, Nbs1, and Rad50 in multiple cell types, including p53- or ARF-deficient cells, and this association did not require functional ATM or BRCA1.
- Mdm2 bound directly to Nbs1, but not to Mre11 or Rad50; Mdm2 amino acids 198–314 were required for M-N-R complex association, and the central region of Nbs1 (amino acids 221–540) mediated binding to Mdm2.
- Mdm2 co-localized with Nbs1 at nuclear foci after γ-irradiation in over 40% of cells where Nbs1 foci were detected, whereas p53 did not co-localize with Nbs1 at these sites.
- Mdm2 overexpression delayed DNA double-strand break repair independent of p53 and ARF; in p53−/− MEFs at 90 min post-irradiation, over 80% of Mdm2-overexpressing cells had tail moments >4 versus less than 50% of vector control cells. The delay required the Nbs1-binding domain but not the ubiquitin ligase domain.
Methods
- Endogenous Mdm2 was immunoprecipitated from HeLa and other cell lysates, followed by silver staining and mass spectrometry; co-immunoprecipitation and Western blotting were used across human and murine cell lines, primary IMR90 fibroblasts, p53−/− ARF−/− and p53−/− Mdm2−/− MEFs, and patient-derived NBS, ATLD, and A-T cells.
- Direct binding was tested with purified GST-Mdm2 and in vitro transcribed/translated [35S]Met-labeled p53, Nbs1, Mre11, and Bax, quantified by phosphorimaging.
- DNA damage localization was assessed by immunofluorescence in IMR90 and NBS fibroblasts after 12 Gy γ-irradiation; DNA repair was measured by neutral comet assay in NIH3T3 cells and p53−/− MEFs after 5 Gy γ-irradiation, with blinded computer scoring of at least 50 cells per interval per cell line.
Limitations
- The paper states that Mdm2 could not be detected in immunoprecipitations of endogenous Nbs1, Mre11, and Rad50, and that further analysis is required to define regulation of Mdm2 localization to nuclear foci, its release from these sites, and the role of Nbs1/Mdm2 interactions in these processes.
- The paper notes that Mdm2 did not co-localize with every Nbs1 focus and that early foci may be fainter and harder to detect, possibly underestimating Mdm2 localization at early foci.
- Evident from the text: many conclusions rely on overexpression systems and established cell lines, and the comet assay measures DNA double-strand breaks but does not establish the precise biochemical mechanism by which Mdm2 delays repair.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 5 Not checked · 60 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Combined, these reports suggest that Mdm2 has functions independent of p53 that contribute to transformation.”
§ Mdm2 Binds to Nbs1 at Sites of DNA Damage and Regulates Double Strand Break Repair* > Abstract
What the sources say
- Not checked — no full text of the sourcecites [31] Jones, 1998, Proc. Natl. Acad. Sci. U. S. A. source
- Supportedcites [32] Lundgren, 1997, Genes Dev. source
The Discussion (page not supplied) says this study demonstrates an MDM2 role independent of p53 inhibition and implies a broader role in cellular transformation. The citing sentence is similarly hedged as a suggestion. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [33] Steinman, 2004, J. Biol. Chem. source
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“However, Mdm2 also has p53-independent activities, and the pathways that mediate these functions are unresolved.”
- Also stated in: § Abstract · hedged
“In addition to p53-dependent functions, mounting evidence suggests Mdm2 also acts independent of p53.”
§ Mdm2 Binds to Nbs1 at Sites of DNA Damage and Regulates Double Strand Break Repair* > Abstract
What the sources say
- Not checked — no full text of the sourcecites [31] Jones, 1998, Proc. Natl. Acad. Sci. U. S. A. source
- Supportedcites [32] Lundgren, 1997, Genes Dev. source
The Discussion states that this study demonstrates a role for MDM2 independent of p53 inhibition. It also says the mechanisms underlying the observed phenotype have not been defined. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [33] Steinman, 2004, J. Biol. Chem. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · hedged
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A forkhead-associated domain and a breast cancer C-terminal domain at the N terminus of Nbs1 are critical for proper nuclear localization of the M-N-R complex to nuclear foci or sites of DNA strand breaks (6).”
§ Mdm2 Binds to Nbs1 at Sites of DNA Damage and Regulates Double Strand Break Repair* > Abstract
What the sources say
- Partly supportedcites [6] Desai-Mehta, 2001, Mol. Cell. Biol. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says amino-terminal sequences are required for radiation-induced focus formation and identifies the FHA and BRCT domains as candidates for that function, not as proven critical domains. It separately assigns nuclear localization to residues 401–652, so the claim conflates focus formation with nuclear localization and overstates the evidence for FHA and BRCT. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“To evaluate whether Mdm2 expression would influence Nbs1-mediated DNA repair, we took advantage of the comet assay, which under neutral conditions measures double strand breaks on a per cell basis (41,42).”
§ Mdm2 Binds to Nbs1 at Sites of DNA Damage and Regulates Double Strand Break Repair* > Nbs1 Mediates the Interaction between
What the sources say
- Not matchedcites [41] Kobayashi, 1995, MMS Commun.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Partly supportedcites [42] Collins, 2004, Mol. Biotechnol. sourceExperimental — accuracy not yet measured
Section 2.2.2 describes a neutral comet-assay procedure designed to detect double-strand breaks, and the Conclusions describe the assay as measuring breaks in single cells. But Section 2.2.2 also says another neutral procedure detected single-strand breaks. Neutral conditions alone therefore do not establish that the assay measures double-strand breaks. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The association of Mdm2 with Nbs1 does not require Mre11, ATM, BRCA1, or p53, although all of these proteins are necessary for a normal cellular response to ionizing irradiation and to maintain DNA integrity (1,45).”
§ Mdm2 Binds to Nbs1 at Sites of DNA Damage and Regulates Double Strand Break Repair* > DISCUSSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
46 more claims
Create a free account to see all 71 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 10
- It may state two separate claims as one. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, in the context of DNA damage, MDM2 localizes to the nucleus and modulates DNA repair in a p53-independent manner by binding to and inactivating Nbs1 in the MRE11/Rad50/NBS1 complex.1,8,27”
From Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist (2017) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mdm2 can modulate the ability of cells to sense DNA damage through its direct binding to Nbs1 of the MRN DNA repair complex (24).”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [24]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recently, we discovered the interaction between Mdm2 and Nbs1”
From Mdm2 Promotes Genetic Instability and Transformation Independent of p53 (2008) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Nbs1, a member of the Mre11/Rad50/Nbs1 complex that functions in DNA double-strand break repair and other functions that are necessary to maintain chromosomal stability (1, 54).”
From Mdm2 Promotes Genetic Instability and Transformation Independent of p53 (2008) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Further, Mdm2 and Nbs1 were found to co-localize together at sites of DNA damage after cells were treated with ionizing radiation to induce double-strand breaks [31].”
From Integration of DNA damage and repair with murine double-minute 2 (Mdm2) in tumorigenesis (2012) · cites this paper as [31]
19 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Dignam, J. D., Lebovitz, R. M., & Roeder, R. G. (1983) · Nucleic Acids Research · doi:10.1093/nar/11.5.1475 · Cited by 11,260
Mass Spectrometric Sequencing of Proteins from Silver-Stained Polyacrylamide Gels
Shevchenko, A., Wilm, M., Vorm, O., & Mann, M. (1996) · Analytical Chemistry · doi:10.1021/ac950914h · Cited by 8,995
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
The Comet Assay for DNA Damage and Repair: Principles, Applications, and Limitations
Collins, A. R. (2004) · Molecular Biotechnology · doi:10.1385/mb:26:3:249 · Cited by 2,892
A Single Ataxia Telangiectasia Gene with a Product Similar to PI-3 Kinase
Savitsky, K., Bar-Shira, A., Gilad, S., Rotman, G., Ziv, Y., Vanagaite, L., Tagle, D. A., Smith, S., Uziel, T., Sfez, S., et al. (1995) · Science · doi:10.1126/science.7792600 · Cited by 2,785
A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage
Paull, T. T., Rogakou, E. P., Yamazaki, V., Kirchgessner, C. U., Gellert, M., & Bonner, W. M. (2000) · Current Biology · doi:10.1016/s0960-9822(00)00610-2 · Cited by 2,098
Activation of the ATM Kinase by Ionizing Radiation and Phosphorylation of p53
Canman, C. E., Lim, D.-S., Cimprich, K. A., Taya, Y., Tamai, K., Sakaguchi, K., Appella, E., Kastan, M. B., & Siliciano, J. D. (1998) · Science · doi:10.1126/science.281.5383.1677 · Cited by 2,042
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951
Research works printed but not linked: 4
- Dang, 2002, Cancer Res., 62, 1222
- Kobayashi, 1995, MMS Commun., 103
- Tomlinson, 1998, Cancer Res., 58, 3237
- Iwakuma, 2003, Mol. Cancer Res., 1, 993
Cited by
The MDM2-p53 pathway revisited
Subhasree, N., Jiangjiang, Q., Kalkunte, S., Minghai, W., & Ruiwen, Z. (2013) · The Journal of Biomedical Research · doi:10.7555/jbr.27.20130030 · Cited by 414
Molecular Pathways: Targeting Mdm2 and Mdm4 in Cancer Therapy
Li, Q., & Lozano, G. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0053 · Cited by 190
Eischen, C. M. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026096 · Cited by 161
Self-citationTargeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?
Nag, S. A., Zhang, X., Srivenugopal, K. S., Wang, M.-H., Wang, W., & Zhang, R. (2014) · Current Medicinal Chemistry · doi:10.2174/09298673113206660325 · Cited by 166
Xu, X., Xiong, X., & Sun, Y. (2016) · Science China Life Sciences · doi:10.1007/s11427-016-0018-0 · Cited by 164
Mahmoudi, M., Gorenne, I., Mercer, J. R., Figg, N., Littlewood, T. D., & Bennett, M. R. (2008) · Circulation Research · doi:10.1161/circresaha.108.182899 · Cited by 149
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
Wang, W., Albadari, N. G., Du, Y., Fowler, J. F., Sang, H. T., Xian, W., McKeon, F., Li, W., Zhou, J., & Zhang, R. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001026 · Cited by 172
Nuclear PI3K signaling in cell growth and tumorigenesis
Davis, W. J., Lehmann, P. Z., & Li, W. (2015) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2015.00024 · Cited by 137
MicroRNA-31 initiates lung tumorigenesis and promotes mutant KRAS-driven lung cancer
Edmonds, M. D., Boyd, K. L., Moyo, T. K., Mitra, R., Duszynski, R. J., Arrate, M. P., Chen, X., Zhao, Z., Blackwell, T. S., Andl, T., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82720 · Cited by 109
Self-citationRibosomal proteins as unrevealed caretakers for cellular stress and genomic instability
Kim, T. H., Leslie, P. L., & Zhang, Y. (2014) · Oncotarget · doi:10.18632/oncotarget.1784 · Cited by 113
Evidence for the Direct Binding of Phosphorylated p53 to Sites of DNA Breaks In vivo
Rashid, S. T. A., Dellaire, G., Cuddihy, A. R., Jalali, F., Vaid, M., Coackley, C. L., Folkard, M., Xu, Y., Chen, B. P. C., Chen, D. J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0729 · Cited by 122
Pathophysiology of B‐Cell Intrinsic Immunoglobulin Class Switch Recombination Deficiencies
Durandy, A., Taubenheim, N., Péron, S., & Fischer, A. (2007) · Advances in immunology · doi:10.1016/s0065-2776(06)94009-7 · Cited by 120
Mdm2 Promotes Genetic Instability and Transformation Independent of p53
Bouska, A., Lushnikova, T., Plaza, S., & Eischen, C. M. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01584-07 · Cited by 105
Self-citationTargeting MDM2 for novel molecular therapy: Beyond oncology
Wang, W., Qin, J., Rajaei, M., Li, X., Yu, X., Hunt, C., & Zhang, R. (2019) · Medicinal Research Reviews · doi:10.1002/med.21637 · Cited by 94
Fåhræus, R., & Olivares‐Illana, V. (2013) · Oncogene · doi:10.1038/onc.2013.410 · Cited by 114
Wang, P., Lushnikova, T., Odvody, J., Greiner, T. C., Jones, S. N., & Eischen, C. M. (2008) · Oncogene · doi:10.1038/sj.onc.1210788 · Cited by 86
Self-citationVogel, K., Bell, L. S., Galloway, A., Ahlfors, H., & Turner, M. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600854 · Cited by 84
The Mdm network and its regulation of p53 activities: a rheostat of cancer risk
Eischen, C. M., & Lozano, G. (2014) · Human Mutation · doi:10.1002/humu.22524 · Cited by 79
Self-citationDurandy, A., Péron, S., & Fischer, A. (2006) · Current Opinion in Rheumatology · doi:10.1097/01.bor.0000231905.12172.b5 · Cited by 84
Mutations of p53 associated with pancreatic cancer and therapeutic implications
Voutsadakis, I. A. (2021) · Annals of Hepato-Biliary-Pancreatic Surgery · doi:10.14701/ahbps.2021.25.3.315 · Cited by 75
Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53
Supiot, S., Hill, R. P., & Bristow, R. G. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0442 · Cited by 77
Mdm2 affects genome stability independent of p53
Bouska, A., & Eischen, C. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3732 · Cited by 71
Self-citationMdmx promotes genomic instability independent of p53 and Mdm2
Carrillo, A. M., Bouska, A., Arrate, M. P., & Eischen, C. M. (2015) · Oncogene · doi:10.1038/onc.2014.27 · Cited by 69
Self-citationHároníková, L., Bonczek, O., Zatloukalová, P., Kokas, F. Z., Kucerikova, M., Coates, P. J., Fåhræus, R., & Vojtěšek, B. (2021) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-021-00293-6 · Cited by 76
Murine double minute 2: p53-independent roads lead to genome instability or death
Bouska, A. C., & Eischen, C. M. (2009) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2009.02.006 · Cited by 72
Self-citationDurandy, A., Péron, S., Taubenheim, N., et al. (2006) · Human Mutation · doi:10.1002/humu.20414 · Cited by 62
Chromatin modifiers Mdm2 and RNF2 prevent RNA:DNA hybrids that impair DNA replication
Klusmann, I., Wohlberedt, K., Magerhans, A., Teloni, F., Korbel, J. O., Altmeyer, M., & Dobbelstein, M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1809592115 · Cited by 65
The Many Faces of MDM2 Binding Partners
Riley, M. F., & Lozano, G. (2012) · Genes & Cancer · doi:10.1177/1947601912455322 · Cited by 72
Mdm2 Is Required for Survival and Growth of p53-Deficient Cancer Cells
Feeley, K. P., Adams, C. M., Mitra, R., & Eischen, C. M. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0809 · Cited by 63
Self-citationDetection of a tandem BRCT in Nbs1 and Xrs2 with functional implications in the DNA damage response
Becker, E., Meyer, V., Madaoui, H., & Guérois, R. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl075 · Cited by 76
Myc Induces miRNA-Mediated Apoptosis in Response to HDAC Inhibition in Hematologic Malignancies
Adams, C. M., Hiebert, S. W., & Eischen, C. M. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1751 · Cited by 53
Self-citationThe Mre11-Nbs1 Interface Is Essential for Viability and Tumor Suppression
Kim, J. H., Grosbart, M., Anand, R., Wyman, C., Ćejka, P., & Petrini, J. H. J. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.035 · Cited by 55
MDM2 promotes genome instability by ubiquitinating the transcription factor HBP1
Cao, Z., Xue, J., Cheng, Y., Wang, J., Liu, Y., Li, H., Jiang, W., Li, G., Gui, Y., & Zhang, X. (2019) · Oncogene · doi:10.1038/s41388-019-0761-2 · Cited by 46
Role of Mdm2 and Mdmx in DNA repair
Eischen, C. M. (2016) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjw052 · Cited by 45
Self-citationWang, H., Cai, S., Bailey, B. J., Reza Saadatzadeh, M., Ding, J., Tonsing-Carter, E., Georgiadis, T. M., Zachary Gunter, T., Long, E. C., Minto, R. E., et al. (2017) · Journal of Neurosurgery · doi:10.3171/2016.1.jns152513 · Cited by 49
Recent Advances in Validating MDM2 as a Cancer Target
Rayburn, E. R., Ezell, S. J., & Zhang, R. (2009) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152009789124628 · Cited by 54
Small-molecule inhibition of MDM2-p53 interaction augments radiation response in human tumors
Werner, L. R., Huang, S., Francis, D. M., Armstrong, E. A., Ma, F., Li, C., Iyer, G., Canon, J., & Harari, P. M. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-1056-t · Cited by 45
“Emerging evidence has linked MDM2 to the radiation-induced DNA damage repair response by a direct binding to Nbs1 that is a critical member of the Mre11-Nbs1-Rad50 repair pathway (10).”
BackgroundWienken, M., Moll, U. M., & Dobbelstein, M. (2016) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjw046 · Cited by 46
Oncogenic Protein MTBP Interacts with MYC to Promote Tumorigenesis
Grieb, B. C., Gramling, M., Arrate, M. P., Chen, X., Beauparlant, S. L., Haines, D. S., Xiao, H., & Eischen, C. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2149 · Cited by 43
Self-citationMacDuff, D. A., Neuberger, M. S., & Harris, R. S. (2005) · Molecular Immunology · doi:10.1016/j.molimm.2005.07.024 · Cited by 48
Tonsing-Carter, E., Bailey, B. J., Saadatzadeh, M. R., Ding, J., Wang, H., Sinn, A. L., Peterman, K. M., Spragins, T. K., Silver, J. M., Sprouse, A. A., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0237 · Cited by 42
Self-citationAging mice have increased chromosome instability that is exacerbated by elevated Mdm2 expression
Lushnikova, T., Bouska, A., Odvody, J., Dupont, W. D., & Eischen, C. M. (2011) · Oncogene · doi:10.1038/onc.2011.172 · Cited by 40
Self-citationCopson, E., White, H., Blaydes, J. P., Robinson, D., Johnson, P., & Eccles, D. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-80 · Cited by 45
The Role of MDM2 in Promoting Genome Stability versus Instability
Saadatzadeh, M. R., Elmi, A. N., Pandya, P. H., Bijangi‐Vishehsaraei, K., Ding, J., Stamatkin, C. W., Cohen‐Gadol, A., & Pollok, K. E. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102216 · Cited by 46
Yu, Z.-C., Huang, Y., & Shieh, S.-Y. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1173 · Cited by 50
MDM2/X inhibitors as radiosensitizers for glioblastoma targeted therapy
Miles, X., Vandevoorde, C., Hunter, A., & Bolcaen, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.703442 · Cited by 40
Structural basis for DNA damage-induced phosphoregulation of MDM2 RING domain
Magnussen, H., Ahmed, S. F., Sibbet, G. J., Hristova, V. A., Nomura, K., Hock, A. K., Archibald, L. J., Jamieson, A. G., Fushman, D., Vousden, K. H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15783-y · Cited by 41
A Novel Nuclear Interactor of ARF and MDM2 (NIAM) That Maintains Chromosomal Stability
Tompkins, V. S., Hagen, J., Frazier, A. A., Lushnikova, T., Fitzgerald, M. P., Tommaso, A. D., Ladevèze, V., Domann, F. E., Eischen, C. M., & Quelle, D. E. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m609612200 · Cited by 42
Self-citationDobbelstein, M., & Levine, A. J. (2020) · Cancer Science · doi:10.1111/cas.14433 · Cited by 45
Splicing Up Mdm2 for Cancer Proteome Diversity
Okoro, D. R., Rosso, M., & Bargonetti, J. (2012) · Genes & Cancer · doi:10.1177/1947601912455323 · Cited by 42
Baydoun, H. H., Pancewicz, J., & Nicot, C. (2011) · Blood · doi:10.1182/blood-2010-08-304600 · Cited by 41
Li, W., Peng, X., Lang, J., & Xu, C. S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00631 · Cited by 39
Smarcal1 and Zranb3 Protect Replication Forks from Myc-Induced DNA Replication Stress
Puccetti, M. V., Adams, C. M., Kushinsky, S., & Eischen, C. M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2705 · Cited by 35
Self-citationMDM2 SNP309 polymorphism and breast cancer risk: a meta-analysis
Zhao, E., Cui, D., Yuan, L., & Lu, W. (2011) · Molecular Biology Reports · doi:10.1007/s11033-011-1119-1 · Cited by 40
Pold3is required for genomic stability and telomere integrity in embryonic stem cells and meiosis
Zhou, Z., Wang, L., Ge, F., Gong, P., Wang, H., Wang, F., Chen, L., & Liu, L. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky098 · Cited by 34
MDM2 binds and ubiquitinates PARP1 to enhance DNA replication fork progression
Giansanti, C., Manzini, V., Dickmanns, A., Dickmanns, A., Palumbieri, M. D., Sanchi, A., Kienle, S. M., Rieth, S., Scheffner, M., Lopes, M., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110879 · Cited by 37
Carrillo, A. M., Hicks, M., Khabele, D., & Eischen, C. M. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0089 · Cited by 31
Self-citationOkoro, D. R., Arva, N. C., Gao, C., Polotskaia, A., Puente, C., Rosso, M., & Bargonetti, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077643 · Cited by 36
Conradt, L., Henrich, A., Wirth, M., Reichert, M., Lesina, M., Algül, H., Schmid, R. M., Krämer, O. H., Saur, D., & Schneider, G. (2013) · International Journal of Cancer · doi:10.1002/ijc.27916 · Cited by 30
“Direct interaction of Nbs1 with Mdm2 was demonstrated.(28,30) Interestingly, overexpression of Mdm2 leads to a delay in DSB repair independent of p53 and the E3 ubiquitin ligase activity of Mdm2, but strictly dependent on Nbs1.”
BackgroundMutations in the Nijmegen Breakage Syndrome Gene in Medulloblastomas
Huang, J., Grotzer, M. A., Watanabe, T., Hewer, E., Pietsch, T., Rutkowski, S., & Ohgaki, H. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0098 · Cited by 35
Decreased Mdm2 expression inhibits tumor development induced by loss of ARF
Wang, P., Greiner, T. C., Lushnikova, T., & Eischen, C. M. (2006) · Oncogene · doi:10.1038/sj.onc.1209411 · Cited by 29
Self-citationMDM2 copy number increase: a poor prognostic, molecular event in esophageal squamous cell carcinoma
Sawada, R., Maehara, R., Oshikiri, T., Nakamura, T., Itoh, T., Kodama, Y., Kakeji, Y., & Zen, Y. (2019) · Human Pathology · doi:10.1016/j.humpath.2019.04.002 · Cited by 33
Zhao, Y., Tan, M., Liu, X., Xiong, X., & Sun, Y. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0192-3 · Cited by 28
Mdm4 supports DNA replication in a p53-independent fashion
Wohlberedt, K., Klusmann, I., Derevyanko, P. K., Henningsen, K. M., Choo, J. A. M. Y., Manzini, V., Magerhans, A., Giansanti, C., Eischen, C. M., Jochemsen, A. G., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1325-1 · Cited by 27
Self-citationAraki, K., Yamashita, T., Reddy, N. P., Wang, H., Abuzeid, W. M., Khan, K., O'Malley, B. W., & Li, D. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605980 · Cited by 32
Targeting the Ubiquitin–Proteasome Pathway In Breast Cancer Therapy
Dees, E. C., & Orlowski, R. Z. (2006) · Future Oncology · doi:10.2217/14796694.2.1.121 · Cited by 25
Novel MDM2 p53‐Independent Functions Identified through RNA Silencing Technologies
Zhang, Z., Wang, H., Li, M., Rayburn, E. R., Agrawal, S., & Zhang, R. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1359.030 · Cited by 24
MDM2 as a Critical Effector of the MYCN Oncogene in Tumorigenesis
Slack, A., & Shohet, J. M. (2005) · Cell Cycle · doi:10.4161/cc.4.7.1790 · Cited by 22
Zhang, R., Ma, J., Avery, J. T., Sambandam, V., Nguyen, T. H.-A., Xu, B., Suto, M. J., & Boohaker, R. J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00241 · Cited by 20
Protecting the genome from mdm2 and mdmx
Melo, A. N., & Eischen, C. M. (2012) · Genes & Cancer · doi:10.1177/1947601912454139 · Cited by 20
Self-citationDefective replication stress response inhibits lymphomagenesis and impairs lymphocyte reconstitution
Puccetti, M. V., Fischer, M. A., Arrate, M. P., Boyd, K. L., Duszynski, R. J., Betous, R., Cortez, D., & Eischen, C. M. (2016) · Oncogene · doi:10.1038/onc.2016.408 · Cited by 19
Self-citationWang, Y., Yu, H., Li, M., Long, J., Zhao, Y.-P., Zhang, J., Li, Q., You, H., Tong, W., Jia, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082426 · Cited by 19
Senturk, J. C., Bohlman, S., & Manfredi, J. J. (2017) · Oncogene · doi:10.1038/onc.2017.229 · Cited by 21
Malmlöf, M., Pääjärvi, G., Högberg, J., & Stenius, U. (2007) · Toxicological Sciences · doi:10.1093/toxsci/kfm305 · Cited by 18
Structure and function of MDM2 and MDM4 in health and disease
Zhu, I. Y., Lloyd, A., Critchley, W. R., Saikia, Q., Jade, D., Divan, A., Zeqiraj, E., Harrison, M. A., Brown, C. J., & Ponnambalam, S. (2025) · Biochemical Journal · doi:10.1042/bcj20240757 · Cited by 29
C9orf72 poly(PR) mediated neurodegeneration is associated with nucleolar stress
Cicardi, M. E., Hallgren, J., Mawrie, D., Krishnamurthy, K., Markandaiah, S. S., Nelson, A. T., Kankate, V., Anderson, E. N., Pasinelli, P., Pandey, U. B., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107505 · Cited by 24
Self-citationEgorova, O., Lau, H. H., McGraphery, K., & Sheng, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041309 · Cited by 20
Watanabe, T., Nobusawa, S., Lu, S., Huang, J., Mittelbronn, M. G. A., & Ohgaki, H. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31819724c2 · Cited by 19
What do we need to know and understand about p53 to improve its clinical value?
Salomao, N., Karakostis, K., Hupp, T., Vollrath, F., Vojtesek, B., & Fahraeus, R. (2021) · The Journal of Pathology · doi:10.1002/path.5677 · Cited by 15
A novel mouse model of rhabdomyosarcoma underscores the dichotomy of MDM2-ALT1 function in vivo
Comiskey, D. F., Jacob, A. G., Sanford, B. L., Montes, M., Goodwin, A., Steiner, H. E., Matsa, E., Tapia-Santos, A. S., Bebee, T. W., Grieves, J. L., et al. (2017) · Oncogene · doi:10.1038/onc.2017.282 · Cited by 16
Pääjärvi, G., Jernström, B., Seidel, A., & Stenius, U. (2007) · Molecular Carcinogenesis · doi:10.1002/mc.20385 · Cited by 17
ARF inhibits the growth and malignant progression of non-small-cell lung carcinoma
Busch, S., Moser, R. D., Gurley, K. E., Kelly‐Spratt, K. S., Liggitt, H. D., & Kemp, C. J. (2013) · Oncogene · doi:10.1038/onc.2013.208 · Cited by 17
Piotrowski, P., Lianeri, M., Rubiś, B., Knuła, H., Rybczyńska, M., Grodecka-Gazdecka, S., & Jagodziński, P. P. (2012) · The International Journal of Biological Markers · doi:10.5301/jbm.2012.9140 · Cited by 14
Immunoglobulin class switch recombination: study through human natural mutants
Durandy, A. (2008) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2008.0210 · Cited by 14
MDM2 Implications for Potential Molecular Pathogenic Therapies of Soft-Tissue Tumors
Sun, S. Y. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12113638 · Cited by 13
Murine double minute 2, a potential p53-independent regulator of liver cancer metastasis
Ranjan, A., Bera, K., & Iwakuma, T. (2016) · Hepatoma Research · doi:10.20517/2394-5079.2015.67 · Cited by 12
Tuna, G., Küçükhüseyin, Ö., Arıkan, S., Saglam, E. K., Güler, E., Cacına, C., Öztop, Ö., Turan, S., Korkmaz, G., & Yaylım, İ. (2013) · DNA and Cell Biology · doi:10.1089/dna.2012.1933 · Cited by 12
Integration of DNA damage and repair with murine double-minute 2 (Mdm2) in tumorigenesis
Lehman, J., & Mayo, L. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131216373 · Cited by 9
MDM2 SNP309 polymorphism is associated with lung cancer risk in women: A meta-analysis using METAGEN
He, W., Long, J., Xian, L., Pang, F., Su, L., WEI, S., Wei, B., & Hu, Y. (2012) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2012.640 · Cited by 10
Fan, Y.-H., Hu, Z., Li, C., Wang, L., Guo, Z., Qiao, Y., Zhang, L., Zhang, W. J., Mao, L., & Wei, Q. (2007) · Journal of Proteome Research · doi:10.1021/pr060655k · Cited by 9
MDM2 in Tumor Biology and Cancer Therapy: A Review of Current Clinical Trials
Russano, F., Sturlese, M., Dall’Olmo, L., Callegarin, F., Brugnolo, D., Fiore, P. D., Patti, V., Purpura, A. H.-S., Moro, S., Rastrelli, M., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010099 · Cited by 17
Goričar, K., Kovač, V., Jazbec, J., Lamovec, J., & Dolžan, V. (2015) · Journal of Medical Biochemistry · doi:10.2478/jomb-2014-0031 · Cited by 8
Regulation of c-Myc and NBS1 by ionizing radiation in glioblastoma cells
Rodrigues, P. M. G., de Souza, R. S., Borges, H. L., & Martins, R. A. P. (2017) · Oncology Signaling · doi:10.1016/j.onsig.2017.12.001 · Cited by 7
Dual functionality of MDM2 in PROTACs expands the horizons of targeted protein degradation
Zhao, J., Chen, H., & Liang, C. (2025) · Biomarker Research · doi:10.1186/s40364-025-00826-7 · Cited by 7
Herok, M., Wawrzynów, B., Maluszek, M. J., Olszewski, M. B., Żylicz, M., & Żylicz, M. (2021) · Cancers · doi:10.3390/cancers13184501 · Cited by 5
The 40bp indel polymorphism of MDM2 increase the risk of cancer: An updated meta-analysis.
Moazeni‐Roodi, A., Ghavami, S., & Hashemi, M. M. (2019) · PubMed · doi:10.22099/mbrc.2019.31527.1364 · Cited by 6
Therapeutic considerations for Mdm2: not just a one trick pony
Lehman, J. A., Eitel, J. A., Batuello, C. N., & Mayo, L. D. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.11.1309 · Cited by 12
ProTargetMiner: A proteome signature library of anticancer molecules for functional discoveryPreprint
Saei, A. A., Chernobrovkin, A. L., Sabatier, P., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/421115 · Cited by 4
Kaur, N. (2023) · Advances In Clinical And Medical Research · doi:10.52793/acmr.2023.4(3)-58 · Cited by 2
Wang, W., Alley, A., Sun, N., Tadesse, M., Wang, X., & Zhang, R. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1663766 · Cited by 7
Metadata
- Authors
- Alt, J. R., Bouska, A., Fernandez, M. R., Cerny, R. L., Xiao, H., & Eischen, C. M.
- Affiliations
- University of Nebraska Medical Center (US)
- University of Nebraska–Lincoln (US)
- Corresponding author
- Eischen, Christine M.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2005-05
- Volume
- 280
- Issue
- 19
- Pages
- 18771-18781
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2085875005
- Cited by
- 131
- References
- 58
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 2 · 2023: 7 · 2022: 2 · 2021: 5 · 2020: 8 · 2019: 7 · 2018: 5 · 2017: 7 · 2016: 8 · 2015: 9 · 2014: 8 · 2013: 6 · 2012: 9
- FWCI
- 3.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 5630 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (RR15635)
- National Cancer Institute (CA-09476, CA-09139, T32CA009139, P30CA036727, T32CA009476)
- National Center for Research Resources (P20RR015635)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- MDM2, NBS1, MRE11, RAD50, DNA double-strand break repair, DNA damage response, p53-independent function, gamma irradiation, forkhead-associated domain
- MeSH terms
- MRE11 Homologue Protein, Amino Acid Sequence, Animals, Cell Line, DNA Damage, DNA Repair, DNA-Binding Proteins, Gamma Rays, Glutathione Transferase, HeLa Cells, Humans, Mice, Transgenic, Microscopy, Fluorescence, Molecular Sequence Data, Mutation, Nuclear Proteins, Protein Binding, Proto-Oncogene Proteins, Time Factors, Blotting, Western, Tumor Suppressor Protein p53, Silver Staining, Sequence Homology, Amino Acid, Protein Structure, Tertiary, Acid Anhydride Hydrolases, DNA, Complementary, Cell Cycle Proteins, K562 Cells, NIH 3T3 Cells, DNA Repair Enzymes, Cell Line, Tumor, Immunoprecipitation, Mice, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.